(Biospecimen and Pathology Core) The translational research proposed in the MD Anderson Cancer Center Prostate Cancer SPORE requires a broad range of comprehensive support. The Biospecimen and Pathology Core supports investigators by providing (1) a biospecimen resource with clinically and pathologically annotated biospecimens that encompass the clinical spectrum of prostate cancer; (2) clinically relevant patient-derived xenografts reflective of the clinical challenges addressed in the projects; (3) clinical and laboratory personnel experienced in the conduct, collection, and processing of specimens from clinical trials; and (4) dedicated pathologists and clinicians with technical expertise who will conduct and interpret tissue-based studies and coordinate all core activities. To maximize analyses using small samples and enhance collaboration among investigators at MD Anderson and other institutions, Core personnel will prepare and distribute tissue derivatives linked with specific disease states. Close collaboration with investigators and electronic processing of requests for biospecimens and clinical information by the Tissue Acquisition and Distribution Committee will ensure the evolving needs of each project will be met in a timely manner. In addition, the Core?s Prometheus informatics staff will manage the repository for clinical and translational data so that investigators will have the full power of detailed, well-curated clinical annotations essential to maximizing the information gained from often small samples. The Prometheus system also facilitates the interpretation of analyses within specific clinical and biologic contexts and enhances interactions among projects. Other functions of Prometheus are to ensure common data format and ontologic term usage, data integrity, audit history, and data security. Prometheus will also facilitate future data exchanges with investigators and SPOREs at other institutions. Finally, Prometheus will enable all statistical analyses performed in the Biostatistics and Bioinformatics Core to be carried out using the most up-to-date clinical and translational data.
(Biospecimen and Pathology Core) The Biospecimen and Pathology Core personnel will collect, store, perform quality control measures, annotate, and distribute tissue and blood specimens obtained from patients with prostate cancer. They will also create and maintain cell lines and xenografts from specimens of prostate tumors. The core personnel will also provide technical support and pathological expertise to the investigators and link the clinical and pathological information with the results obtained in the various experiments.
|Velazquez-Torres, Guermarie; Shoshan, Einav; Ivan, Cristina et al. (2018) A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nat Commun 9:461|
|Zanoaga, Oana; Jurj, Ancuta; Raduly, Lajos et al. (2018) Implications of dietary ?-3 and ?-6 polyunsaturated fatty acids in breast cancer. Exp Ther Med 15:1167-1176|
|Zhang, Wei; Liu, Bo; Wu, Wenhui et al. (2018) Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res 24:696-707|
|Monroig-Bosque, Paloma Del C; Shah, Maitri Y; Fu, Xiao et al. (2018) OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers. Sci Rep 8:13106|
|Basourakos, Spyridon P; Davis, John W; Chapin, Brian F et al. (2018) Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int 121:69-76|
|Pan, Tianhong; Lin, Song-Chang; Yu, Kai-Jie et al. (2018) BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. Neoplasia 20:32-43|
|Yu-Lee, Li-Yuan; Yu, Guoyu; Lee, Yu-Chen et al. (2018) Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGF?RIII-p38MAPK-pS249/T252RB Pathway. Cancer Res 78:2911-2924|
|Luo, Yong; Azad, Abul Kalam; Karanika, Styliani et al. (2018) Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models. Int J Cancer 142:2163-2174|
|Soundararajan, Rama; Aparicio, Ana M; Logothetis, Christopher J et al. (2018) Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers. Front Oncol 8:69|
|Class, Caleb A; Ha, Min Jin; Baladandayuthapani, Veerabhadran et al. (2018) iDINGO-integrative differential network analysis in genomics with Shiny application. Bioinformatics 34:1243-1245|
Showing the most recent 10 out of 217 publications